<DOC>
	<DOCNO>NCT00604058</DOCNO>
	<brief_summary>The present study intend investigate use fractional dos sanofi pasteur 's IMOVAX Polio inject intradermally . The primary objective demonstrate non-inferiority fractional dos IMOVAX Polio administer intradermally versus full dos IMOVAX Polio administer intramuscularly , term seroprotection rate ( polio type 1 , 2 3 ) one month three-dose primary vaccination administer 6-10-14 week age .</brief_summary>
	<brief_title>Immunogenicity Safety Fractional Doses IPV Intradermally v Full Doses Intramuscularly</brief_title>
	<detailed_description />
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria check screen visit ( SC ) : Aged 0 7 day day screen Born full term pregnancy ( ≥37 week ) birth weight ≥2.5 kg Informed consent form sign parent ( ) legally acceptable representative Subjects parent/guardian able attend schedule visit comply trial procedure Inclusion Criteria check randomization visit ( V01 ) : Aged 42 50 day day inclusion Subjects parent/guardian able attend schedule visit comply trial procedure Exclusion Criteria check screen visit ( SC ) : Planned participation another clinical trial present trial period Illness could interfere trial conduct completion , opinion investigator Receipt blood bloodderived product since birth might interfere assessment immune response History seizures Known personal maternal Human Immunodeficiency Virus ( HIV ) , Hepatitis B antigen Hepatitis C seropositivity Thrombocytopenia bleed disorder contraindicate IM injection Exclusion Criteria check randomization visit ( V01 ) : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance Chronic illness stage could interfere trial conduct completion , opinion investigator Receipt blood bloodderived product since birth might interfere assessment immune response Receipt plan receipt vaccine 4 week precede follow trial vaccination ( except BCG , DTPHib Hepatitis B vaccine , give within 10 day study vaccination ) History seizure Known personal maternal Human Immunodeficiency Virus ( HIV ) , Hepatitis B antigen Hepatitis C seropositivity History poliomyelitis infection ( confirm either clinically , serologically microbiologically ) Previous vaccination poliomyelitis disease either trial vaccine another vaccine Thrombocytopenia , bleed disorder anticoagulant 3 week precede inclusion contraindicate intramuscular ( IM ) injection Febrile illness ( temperature ≥38°C ) moderate severe acute illness/infection day vaccination , accord investigator judgment</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>50 Days</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Poliomyelitis</keyword>
	<keyword>intradermal</keyword>
</DOC>